SCHEMBL685385

SCHEMBL685385

CN1CCC[C@@H](O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10217 1.00
SCHEMBL10796 1.00
SCHEMBL3359569 1.00
Water SCHEMBL27587846 0.97 CA12 (0.42)
Ethane SCHEMBL7360363 0.97 CA12 (0.42)
Methane SCHEMBL3247537 0.97
Hydrochloric Acid SCHEMBL31732955 0.97
Hydrochloric Acid SCHEMBL27149835 0.97
SCHEMBL24086950 0.92
SCHEMBL15495008 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630562-B2 Piperidylurea compounds and methods of use thereof ARCUS BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
EP-4142732-B1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-20260042777-A1 PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-02-12 US disclosed
US-20250270188-A1 NLRP3 INFLAMMASOME INHIBITORS NOVARTIS AG (CH) 2025-08-28 US disclosed
CN-119841831-A Fused heterocyclic NLRP3 inhibitor compound, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2025-04-18 CN disclosed
US-20250109122-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2025-04-03 US disclosed
CN-119732956-A NLRP3 inflammatory corpuscle inhibitor 诺华股份有限公司 2025-04-01 CN disclosed
CN-113784957-B NLRP3 inflammatory corpuscle inhibitor 诺华股份有限公司 2025-02-28 CN disclosed
US-12202817-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2025-01-21 US disclosed
US-12139471-B2 NLRP3 inflammasome inhibitors NOVARTIS AG (CH) 2024-11-12 US disclosed
EP-1831208-A1 QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS Novartis AG (CH) 2007-09-12 EP disclosed
EP-1377556-B1 PYRAZOLE DERIVATIVES FOR TREATING HIV PFIZER LTD (GB) 2007-04-04 EP disclosed
US-20060287362-A1 Organic compounds NOVARTIS AG (CH) 2006-12-21 US disclosed
WO-2006112778-A1 NEW MUSCARINIC RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2006-10-26 WO disclosed
CN-1805935-A Piperidinium and pyrrolidinium derivatives as muscarinic M3 receptor ligands NORVARTIS AG (CH) 2006-07-19 CN disclosed
WO-2006066929-A1 QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS NOVARTIS AG (CH) 2006-06-29 WO disclosed
EP-1638940-A2 PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS FOR THE MUSCARINIC M3 RECEPTOR Novartis AG (CH) 2006-03-29 EP disclosed
US-20050101595-A1 N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use PFIZER INC. 2005-05-12 US disclosed
WO-2005000815-A2 PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS FOR THE MUSCARINIC M3 RECEPTOR NOVARTIS AG (CH) 2005-01-06 WO disclosed
EP-1369414-A1 Enantiomerically pure Arylcycloalkyl hydroxycarboxylic esters, processes for their preparation and their use as modulators of muscarinic receptors Noe, Christian R. (AT) 2003-12-10 EP disclosed